Novartis licenses three novel anti-infective programs to Boston Pharmaceuticals
- clinical and pre-clinical stage programs focused on addressing growing need for new treatments against drug resistant Gram-negative bacteria
- Agreement is part of Novartis strategy to partner with like-minded innovators to further develop new medicines to address global health challenges
- Research and development for new medicines to treat tropical diseases continues through the Novartis Institute for Tropical Diseases
- LYS228 is a potential best-in-class monobactam which has entered clinical development and which has demonstrated activity against CRE with resistance caused by serine beta-lactamases (SBLs) and/or metallo beta-lactamases (MBLs);
- IID572 is a novel beta-lactamase inhibitor that may be used in combination with LYS228 or other beta-lactam antibiotics to expand their use against difficult-to-treat infections caused by a broader spectrum of CRE; and
- MAK181 is an oral, first-in-class LpxC inhibitor for Pseudomonas infections.
# # #
Novartis Media Relations Central media line: +41 61 324 2200 E-mail: media.relations@novartis.comEric Althoff Novartis Global Media Relations +41 61 324 7999 (direct) +41 79 593 4202 (mobile) eric.althoff@novartis.com | Kara Cournoyer Novartis Institutes for BioMedical Research +1 617 871 3208 (direct) +1 617 710 5447 (mobile) kara.cournoyer@novartis.co |